Skip to main content
UniHealth

Doctor search

Vivek Charu, MD

Pathology · Stanford

NPI 1164964466

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Charu’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence A162607 · Current

Licensed to practise in California · since 2019 · expires 2027-05-31 · Johns Hopkins University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$15,123

Medicare paid this office $15,123 for 55 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Antibody evaluation, each additional single antibody stain procedure29$5,714$26
Electron microscopy for diagnosis25$1,748$70
Special stained specimen slides to examine tissue including interpretation and report40$1,235$11
Pathology examination of tissue using a microscope, moderately high complexity16$1,184$74
Surgical pathology consultation and report on referred slides prepared elsewhere13$979$75
See all 10 services
Every Original Medicare service billed
Antibody evaluation, each additional single antibody stain procedure29$5,714$26
Electron microscopy for diagnosis25$1,748$70
Special stained specimen slides to examine tissue including interpretation and report40$1,235$11
Pathology examination of tissue using a microscope, moderately high complexity16$1,184$74
Surgical pathology consultation and report on referred slides prepared elsewhere13$979$75
Antibody evaluation, initial single antibody stain procedure29$968$32
Special stained specimen slides to examine tissue, initial procedure27$913$31
Pathology examination of tissue using a microscope, intermediate complexity23$821$33
Special stained specimen slides to examine tissue, each additional procedure13$555$25
Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report16$287$18

Who their Medicare patients are

55 Original Medicare patients in 2024. Average age 65 · Under 65 31% · Women 44% · Also on Medicaid 49% · Health risk score 3.75. Sicker patients than 9 in 10 peers; the typical pathology clinician is at 1.55.

Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 51% · Heart failure 35% · Coronary heart disease 29% · Atrial fibrillation 25% · COPD 22% · Cancer 20%.

The office billed $198,334, Medicare allowed $18,993 and paid $15,123; for 524 services of 16 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202455524653.75$198,334$15,123
202346437662.41$127,633$12,158
202253521682.89$107,588$14,371
202156575633.21$101,013$15,873
202038434633.27$72,924$12,082

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 7 services

Original Medicare services billed in 2023
Antibody evaluation, each additional single antibody stain procedure21$4,569$27
Electron microscopy for diagnosis19$1,375$72
Pathology examination of tissue using a microscope, intermediate complexity27$1,250$35
Special stained specimen slides to examine tissue including interpretation and report34$1,220$11
Antibody evaluation, initial single antibody stain procedure21$699$33
Special stained specimen slides to examine tissue, initial procedure17$649$32
Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report20$378$19

2022: 9 services

Original Medicare services billed in 2022
Antibody evaluation, each additional single antibody stain procedure24$5,122$27
Electron microscopy for diagnosis22$1,586$72
Special stained specimen slides to examine tissue including interpretation and report43$1,457$11
Pathology examination of tissue using a microscope, moderately high complexity16$1,224$76
Pathology examination of tissue using a microscope, intermediate complexity29$1,165$32
Special stained specimen slides to examine tissue, initial procedure27$905$29
Antibody evaluation, initial single antibody stain procedure24$834$33
Special stained specimen slides to examine tissue, each additional procedure13$679$24
Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report22$425$19

2021: 9 services

Original Medicare services billed in 2021
Antibody evaluation, each additional single antibody stain procedure28$5,706$27
Electron microscopy for diagnosis25$1,833$73
Special stained specimen slides to examine tissue including interpretation and report51$1,732$11
Pathology examination of tissue using a microscope, intermediate complexity39$1,629$35
Special stained specimen slides to examine tissue, initial procedure29$993$33
Antibody evaluation, initial single antibody stain procedure28$985$34
Pathology examination of tissue using a microscope, moderately high complexity11$863$78
Special stained specimen slides to examine tissue, each additional procedure16$780$27
Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report25$502$20

2020: 7 services

Original Medicare services billed in 2020
Antibody evaluation, each additional single antibody stain procedure22$4,899$28
Pathology examination of tissue using a microscope, intermediate complexity31$1,433$37
Special stained specimen slides to examine tissue including interpretation and report36$1,347$12
Electron microscopy for diagnosis18$1,342$75
Antibody evaluation, initial single antibody stain procedure22$871$35
Special stained specimen slides to examine tissue, initial procedure18$722$34
Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report21$513$21

Medicaid work

$529 in 2024

Medicaid paid $529 for 21 billed services this clinician did in 2024, up to 14 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry21$529
Medicaid work by year
202421114$529
202370319$3,867
202227114$2,001
202113113$868
202038214$1,657
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry37$2,228
TISSUE EXAM BY PATHOLOGIST15$950
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure18$688

2022

Largest Medicaid services in 2022
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry27$2,001

2021

Largest Medicaid services in 2021
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry13$868

2020

Largest Medicaid services in 2020
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry26$1,377
TISSUE EXAM BY PATHOLOGIST12$280

Money from drug and device companies

$45 in 2025

Industry payments by year
202511None$45
202311$1,575$1,575

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Novartis PharmaceuticalsNone$45
1 payment
  • Meals · 2025-03-24 · $45
See the published payment
Every published payment
Novartis PharmaceuticalsMeals · 2025-03-24None$45
See earlier years (2023)

2023: $1,575

Payments by company in 2023
Novartis PharmaceuticalsNone$1,575
1 payment
  • Consulting · 2023-04-18 · $1,575

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · Lnp-Ms -111662 Challenges in Iga Nephropathy Management: An Era of Complement Inhibition · 2023This clinician$17,060
Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2024This clinician$12,650

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1164964466
Licence
CA A162607California A162607: Current · expires 2027-05-31
Trained
Johns Hopkins University School of Medicine, 2017
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZP0101X (207ZP0101X)
Mailing address
300 Pasteur Dr Bldg L235, Stanford, CA, 94305
NPI first listed
2016-11-17
NPI last updated
2024-03-13
NPI record certified
2024-03-13

This is when the NPI record was last certified, not a medical board exam.